Prostate Cancer in 2021: Novelties in Prognostic and Therapeutic Biomarker Evaluation
Alessia Cimadamore(University of Udine), Rodolfo Montironi(Marche Polytechnic University), Roberta Mazzucchelli(University of Foggia), Marina Scarpelli(Marche Polytechnic University), Liang Cheng(Brown University), Matteo Santoni(University of Macerata), Antonio López-Beltrán(University of Córdoba), Francesco Massari(Altera (United States))
Cited by 15
Related Papers
Molecular testing for BRAF mutations to inform melanoma treatment decisions: a move toward precision medicine
|Modern Pathology|2017|404
Immune Checkpoint Inhibitors for the Treatment of Bladder Cancer
|Cancers|2021|289